Published in Hepatology on January 01, 1998
Mouse models in non-alcoholic fatty liver disease and steatohepatitis research. Int J Exp Pathol (2006) 3.46
CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. J Clin Invest (2000) 3.17
CYP2E1 and oxidative liver injury by alcohol. Free Radic Biol Med (2007) 2.93
Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease. Semin Liver Dis (2008) 2.89
Pathogenesis of non-alcoholic fatty liver disease. QJM (2009) 2.50
Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design. Contemp Clin Trials (2008) 2.17
NASH is an Inflammatory Disorder: Pathogenic, Prognostic and Therapeutic Implications. Gut Liver (2012) 1.70
Aging is a risk factor of nonalcoholic fatty liver disease in premenopausal women. World J Gastroenterol (2012) 1.68
Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of nonalcoholic fatty liver disease. Drug Metab Dispos (2009) 1.67
Non invasive fibrosis biomarkers reduce but not substitute the need for liver biopsy. World J Gastroenterol (2006) 1.63
Molecular mechanisms and the role of saturated fatty acids in the progression of non-alcoholic fatty liver disease. Prog Lipid Res (2012) 1.51
Treatment of nonalcoholic fatty liver disease in children: TONIC trial design. Contemp Clin Trials (2009) 1.48
Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial. Hepatology (2011) 1.47
Nonalcoholic fatty liver disease: an overview of current insights in pathogenesis, diagnosis and treatment. World J Gastroenterol (2008) 1.43
Female hepatology: favorable role of estrogen in chronic liver disease with hepatitis B virus infection. World J Gastroenterol (2007) 1.43
Oxidative stress and antioxidants in hepatic pathogenesis. World J Gastroenterol (2010) 1.40
Redox mechanisms in hepatic chronic wound healing and fibrogenesis. Fibrogenesis Tissue Repair (2008) 1.30
Gender and racial differences in nonalcoholic fatty liver disease. World J Hepatol (2014) 1.29
Increased apoptosis in high-fat diet-induced nonalcoholic steatohepatitis in rats is associated with c-Jun NH2-terminal kinase activation and elevated proapoptotic Bax. J Nutr (2008) 1.26
Adipocytokines and liver disease. J Gastroenterol (2008) 1.25
Liver-specific beta-catenin knockout mice exhibit defective bile acid and cholesterol homeostasis and increased susceptibility to diet-induced steatohepatitis. Am J Pathol (2009) 1.23
Inflammation and fibrogenesis in steatohepatitis. J Gastroenterol (2012) 1.21
Treatment of non-alcoholic fatty liver disease. Ther Clin Risk Manag (2007) 1.18
N-acetylcysteine attenuates progression of liver pathology in a rat model of nonalcoholic steatohepatitis. J Nutr (2008) 1.15
Hepatoprotective effects of S-adenosyl-L-methionine against alcohol- and cytochrome P450 2E1-induced liver injury. World J Gastroenterol (2010) 1.13
Role of alcohol metabolism in non-alcoholic steatohepatitis. PLoS One (2010) 1.13
PPAR/RXR Regulation of Fatty Acid Metabolism and Fatty Acid omega-Hydroxylase (CYP4) Isozymes: Implications for Prevention of Lipotoxicity in Fatty Liver Disease. PPAR Res (2010) 1.11
Diabetes mellitus increases the in vivo activity of cytochrome P450 2E1 in humans. Br J Clin Pharmacol (2003) 1.11
Role of CYP2E1 in ethanol-induced oxidant stress, fatty liver and hepatotoxicity. Dig Dis (2011) 1.10
Similarities and differences in the pathogenesis of alcoholic and nonalcoholic steatohepatitis. Semin Liver Dis (2009) 1.08
Drug metabolism alterations in nonalcoholic fatty liver disease. Drug Metab Rev (2011) 1.07
Elevated liver function enzymes are related to the development of prediabetes and type 2 diabetes in younger adults: the Bogalusa Heart Study. Diabetes Care (2011) 1.05
Expression of p53, Bax and Bcl-2 proteins in hepatocytes in non-alcoholic fatty liver disease. World J Gastroenterol (2006) 1.04
Cholesterol-fed rabbit as a unique model of nonalcoholic, nonobese, non-insulin-resistant fatty liver disease with characteristic fibrosis. J Gastroenterol (2006) 1.03
Diet-induced obesity is associated with hyperleptinemia, hyperinsulinemia, hepatic steatosis, and glomerulopathy in C57Bl/6J mice. Endocrine (2009) 1.00
Alcohol steatosis and cytotoxicity: the role of cytochrome P4502E1 and autophagy. Free Radic Biol Med (2012) 0.99
Oxidative stress, cardiolipin and mitochondrial dysfunction in nonalcoholic fatty liver disease. World J Gastroenterol (2014) 0.99
Chronic oxidative stress sensitizes hepatocytes to death from 4-hydroxynonenal by JNK/c-Jun overactivation. Am J Physiol Gastrointest Liver Physiol (2009) 0.98
Update information on drug metabolism systems--2009, part II: summary of information on the effects of diseases and environmental factors on human cytochrome P450 (CYP) enzymes and transporters. Curr Drug Metab (2010) 0.98
The role of the nuclear receptor constitutive androstane receptor in the pathogenesis of non-alcoholic steatohepatitis. Gut (2006) 0.98
The pathogenesis of ethanol versus methionine and choline deficient diet-induced liver injury. Biochem Pharmacol (2007) 0.98
Lipotoxicity in the liver. World J Hepatol (2013) 0.97
Methionine deficiency and hepatic injury in a dietary steatohepatitis model. Dig Dis Sci (2007) 0.97
Mitochondria and redox signaling in steatohepatitis. Antioxid Redox Signal (2011) 0.96
Ethanol-induced oxidative stress via the CYP2E1 pathway disrupts adiponectin secretion from adipocytes. Alcohol Clin Exp Res (2011) 0.96
Inhibition of autophagy promotes CYP2E1-dependent toxicity in HepG2 cells via elevated oxidative stress, mitochondria dysfunction and activation of p38 and JNK MAPK. Redox Biol (2013) 0.94
Hepatic steatosis: a benign disease or a silent killer. World J Gastroenterol (2008) 0.92
Lipidomic changes in rat liver after long-term exposure to ethanol. Toxicol Appl Pharmacol (2011) 0.92
Bariatric surgery-induced weight loss reduces hepatic lipid peroxidation levels and affects hepatic cytochrome P-450 protein content. Ann Surg (2010) 0.91
Inflammatory mediators of hepatic steatosis. Mediators Inflamm (2010) 0.91
Acetaminophen pharmacokinetics in children with nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr (2011) 0.91
Genetic differences in oxidative stress and inflammatory responses to diet-induced obesity do not alter liver fibrosis in mice. Liver Int (2009) 0.90
Role of Nrf2 in chronic liver disease. World J Gastroenterol (2014) 0.90
Drug disposition in pathophysiological conditions. Curr Drug Metab (2012) 0.90
DNA damage response and sphingolipid signaling in liver diseases. Surg Today (2015) 0.90
Molecular Interactions between NAFLD and Xenobiotic Metabolism. Front Genet (2013) 0.88
A Guide to Non-Alcoholic Fatty Liver Disease in Childhood and Adolescence. Int J Mol Sci (2016) 0.87
Non-alcoholic Fatty Liver Disease: East Versus West. J Clin Exp Hepatol (2012) 0.87
Anti-oxidative and anti-inflammatory effects of spirulina on rat model of non-alcoholic steatohepatitis. J Clin Biochem Nutr (2012) 0.87
Effects of resveratrol and other polyphenols in hepatic steatosis. World J Gastroenterol (2014) 0.85
Lycopene prevents development of steatohepatitis in experimental nonalcoholic steatohepatitis model induced by high-fat diet. Vet Med Int (2010) 0.85
Functional roles of protein nitration in acute and chronic liver diseases. Oxid Med Cell Longev (2014) 0.85
Role of diet on non-alcoholic fatty liver disease: An updated narrative review. World J Hepatol (2015) 0.83
The generation of carcinogenic etheno-DNA adducts in the liver of patients with nonalcoholic fatty liver disease. Hepatobiliary Surg Nutr (2015) 0.82
Short term feeding of a high fat diet exerts an additive effect on hepatocellular damage and steatosis in liver-specific PTEN knockout mice. PLoS One (2014) 0.81
The role of reactive oxygen species (ROS) and cytochrome P-450 2E1 in the generation of carcinogenic etheno-DNA adducts. Redox Biol (2014) 0.81
HFE gene in primary and secondary hepatic iron overload. World J Gastroenterol (2007) 0.81
Long-term exposure to abnormal glucose levels alters drug metabolism pathways and insulin sensitivity in primary human hepatocytes. Sci Rep (2016) 0.81
Dietary supplements and pediatric non-alcoholic fatty liver disease: Present and the future. World J Hepatol (2015) 0.80
Effects of dietary inulin, statin, and their co-treatment on hyperlipidemia, hepatic steatosis and changes in drug-metabolizing enzymes in rats fed a high-fat and high-sucrose diet. Nutr Metab (Lond) (2012) 0.80
Hepatoprotective and antioxidant effects of lycopene on non-alcoholic fatty liver disease in rat. World J Gastroenterol (2016) 0.79
Relationship between genetic polymorphism of cytochrome P450IIE1 and fatty liver. World J Gastroenterol (2003) 0.79
Metabolic syndrome and hepatic resection: improving outcome. HPB (Oxford) (2011) 0.78
The Combination of S-adenosylmethionine and Dilinoleoylphosphatidylcholine Attenuates Non-alcoholic Steatohepatitis Produced in Rats by a High-Fat Diet. Nutr Res (2007) 0.78
OSAS-related inflammatory mechanisms of liver injury in nonalcoholic fatty liver disease. Mediators Inflamm (2015) 0.78
Mechanism of action of gypenosides on type 2 diabetes and non-alcoholic fatty liver disease in rats. World J Gastroenterol (2015) 0.78
Autoantibodies in liver disease: important clues for the diagnosis, disease activity and prognosis. Auto Immun Highlights (2013) 0.78
Regulation of the effects of CYP2E1-induced oxidative stress by JNK signaling. Redox Biol (2014) 0.78
Do symbiotic and Vitamin E supplementation have favorite effects in nonalcoholic fatty liver disease? A randomized, double-blind, placebo-controlled trial. J Res Med Sci (2016) 0.77
Role of CYP2E1 in mitochondrial dysfunction and hepatic tissue injury in alcoholic and non-alcoholic diseases. Curr Mol Pharmacol (2015) 0.77
In vitro treatment of HepG2 cells with saturated fatty acids reproduces mitochondrial dysfunction found in nonalcoholic steatohepatitis. Dis Model Mech (2014) 0.77
Detection of carcinogenic etheno-DNA adducts in children and adolescents with non-alcoholic steatohepatitis (NASH). Hepatobiliary Surg Nutr (2015) 0.77
Rice Germosprout Extract Protects Erythrocytes from Hemolysis and the Aorta, Brain, Heart, and Liver Tissues from Oxidative Stress In Vitro. Evid Based Complement Alternat Med (2016) 0.77
Nonalcoholic Fatty liver disease from the perspective of an internist. Ochsner J (2002) 0.77
NADPH oxidase is implicated in the pathogenesis of oxidative phosphorylation dysfunction in mice fed a high-fat diet. Sci Rep (2016) 0.75
Statins and their interactions with other lipid-modifying medications: safety issues in the elderly. Ther Adv Drug Saf (2012) 0.75
Biological effects of pyrroloquinoline quinone on liver damage in Bmi-1 knockout mice. Exp Ther Med (2015) 0.75
Glycosylation site occupancy in health, congenital disorder of glycosylation and fatty liver disease. Sci Rep (2016) 0.75
Study of the effects of monacolin k and other constituents of red yeast rice on obesity, insulin-resistance, hyperlipidemia, and nonalcoholic steatohepatitis using a mouse model of metabolic syndrome. Evid Based Complement Alternat Med (2012) 0.75
Induction of CYP2E1 in non-alcoholic fatty liver diseases. Exp Mol Pathol (2015) 0.75
Over-expression of CYP2E1 mRNA and protein: implications of xenobiotic induced damage in patients with de novo acute myeloid leukemia with inv(16)(p13.1q22); CBFβ-MYH11. Int J Environ Res Public Health (2012) 0.75
Identification of cytochrome CYP2E1 as critical mediator of synergistic effects of alcohol and cellular lipid accumulation in hepatocytes in vitro. Oncotarget (2015) 0.75
Multi-omic profiles of hepatic metabolism in TPN-fed preterm pigs administered new generation lipid emulsions. J Lipid Res (2016) 0.75
Preventive effects of dietary walnuts on high-fat-induced hepatic fat accumulation, oxidative stress and apoptosis in mice. J Nutr Biochem (2016) 0.75
Hepatobiliary quiz-6 (2013). J Clin Exp Hepatol (2013) 0.75
Toxicological Implications of Mitochondrial Localization of CYP2E1. Toxicol Res (Camb) (2017) 0.75
Role of nonalcoholic fatty liver disease as risk factor for drug-induced hepatotoxicity. J Clin Transl Res (2017) 0.75
The CAGE questionnaire: validation of a new alcoholism screening instrument. Am J Psychiatry (1974) 16.18
Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. Circulation (1995) 3.82
Plasma immunoglobulin concentrations in a West African (Gambian) community and in a group of healthy British adults. Clin Exp Immunol (1968) 3.53
Seclusion in prison strip cells. BMJ (1993) 3.44
Metabolic gene polymorphism frequencies in control populations. Cancer Epidemiol Biomarkers Prev (2001) 3.43
Dynamics and species richness of tropical rain forests. Proc Natl Acad Sci U S A (1994) 3.32
Orphan nuclear receptors constitutive androstane receptor and pregnane X receptor share xenobiotic and steroid ligands. J Biol Chem (2000) 3.23
[Low risk of cancer after treatment of hyperthyroidism with iodine-131]. Lakartidningen (1992) 3.22
CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. J Clin Invest (2000) 3.17
Disassociation between debrisoquine hydroxylation phenotype and genotype among Chinese. Lancet (1989) 2.96
Risk of second malignant neoplasms among long-term survivors of testicular cancer. J Natl Cancer Inst (1997) 2.83
Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis (2001) 2.63
The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module. Mol Pharmacol (1999) 2.49
Antigens associated with Plasmodium falciparum infections in man. Lancet (1969) 2.45
Prospective evaluation of serum CA 125 levels for early detection of ovarian cancer. Obstet Gynecol (1992) 2.43
Cytochrome P450 pharmacogenetics and cancer. Oncogene (2006) 2.38
Hepatitis C virus in intravenous drug users. Med J Aust (1990) 2.33
Radiation-induced breast cancer: long-term follow-up of radiation therapy for benign breast disease. J Natl Cancer Inst (1993) 2.29
Androgen-induced hepatoma. Lancet (1975) 2.21
Macrophage migration inhibitory factor in rheumatoid arthritis: evidence of proinflammatory function and regulation by glucocorticoids. Arthritis Rheum (1999) 2.17
The cost effectiveness of alpha interferon in the treatment of chronic active hepatitis C. Med J Aust (1994) 2.15
Barriers to hepatitis C transmission within breathing systems: efficacy of a pleated hydrophobic filter. Anaesth Intensive Care (1997) 2.14
Second primary malignancies in thyroid cancer patients. Br J Cancer (2003) 2.10
Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol (1994) 2.09
Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci U S A (1993) 2.08
In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576. Cancer Res (2001) 1.95
Nomenclature for human CYP2D6 alleles. Pharmacogenetics (1996) 1.91
Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine. Lancet (1993) 1.87
Increased hepatocyte CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation. Gastroenterology (1996) 1.83
Effect of chronic coadministration of endotoxin and ethanol on rat liver pathology and proinflammatory and anti-inflammatory cytokines. Hepatology (1999) 1.81
Nonalcoholic steatosis and steatohepatitis. II. Cytochrome P-450 enzymes and oxidative stress. Am J Physiol Gastrointest Liver Physiol (2001) 1.79
Rat liver microsomal NADPH-supported oxidase activity and lipid peroxidation dependent on ethanol-inducible cytochrome P-450 (P-450IIE1). Biochem Pharmacol (1989) 1.78
Prevalence of genetic haemochromatosis among diabetic patients. Lancet (1989) 1.78
The community's tolerance of the mentally ill. Br J Psychiatry (1993) 1.77
Which patients with hepatitis C develop liver complications? Hepatology (2000) 1.73
The primary effect of the Ity locus is on the rate of growth of Salmonella typhimurium that are relatively protected from killing. J Immunol (1990) 1.71
Cancer risk after iodine-131 therapy for hyperthyroidism. J Natl Cancer Inst (1991) 1.71
Kupffer cell inactivation alleviates ethanol-induced steatosis and CYP2E1 induction but not inflammatory responses in rat liver. J Hepatol (2000) 1.69
Results of a consecutive series of patients receiving only antiplatelet therapy after optimized stent implantation. Comparison of aspirin alone versus combined ticlopidine and aspirin therapy. Circulation (1997) 1.68
Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population. Biochem Biophys Res Commun (1999) 1.66
Plasma membrane hydroxyethyl radical adducts cause antibody-dependent cytotoxicity in rat hepatocytes exposed to alcohol. Gastroenterology (1997) 1.63
Risk of leukemia after platinum-based chemotherapy for ovarian cancer. N Engl J Med (1999) 1.63
Initial experience with the disarticulated (one-half) Palmaz-Schatz stent: a technical report. Cathet Cardiovasc Diagn (1992) 1.61
Cervical screening for women with learning disability. Numbers screened can be optimised by using a focused initiative. BMJ (1999) 1.60
Nitrogen inhalation as a method of euthanasia in dogs. Am J Vet Res (1978) 1.57
Spectrophotometric intracutaneous analysis: a new technique for imaging pigmented skin lesions. Br J Dermatol (2002) 1.54
Treatment-associated leukemia following testicular cancer. J Natl Cancer Inst (2000) 1.54
Cardiovascular disease associated with radiotherapy: activation of nuclear factor kappa-B. J Intern Med (2011) 1.52
Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J Pharmacol Exp Ther (1996) 1.51
Soluble antigens in the blood of African patients with severe plasmodium falciparum malaria. Lancet (1968) 1.50
Effects of short-term ethanol and nutrition on the hepatic microsomal monooxygenase system in a model utilizing total enteral nutrition in the rat. Alcohol Clin Exp Res (1991) 1.50
Antipyrine clearance and response to interferon treatment in patients with chronic active hepatitis C. Hepatology (1995) 1.41
Role of cytochrome P4502E1-dependent formation of hydroxyethyl free radical in the development of liver damage in rats intragastrically fed with ethanol. Hepatology (1996) 1.41
Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population. Clin Pharmacol Ther (1992) 1.41
Intracoronary stent implantation in native coronary arteries and saphenous vein grafts: a consecutive experience with six types of stents without prolonged anticoagulation. Mayo Clin Proc (1997) 1.39
Screening for genetic haemochromatosis in a rheumatology clinic. Aust N Z J Med (1994) 1.39
Characterization of radiation-induced apoptosis in the small intestine and its biological implications. Int J Radiat Biol (1994) 1.38
Confusion, cortical blindness and fever. Med J Aust (1995) 1.38
Evaluation of the off-label usage of rituximab in a large teaching hospital in New South Wales. Intern Med J (2007) 1.37
Activation of protein kinase C by lipoxin A and other eicosanoids. Intracellular action of oxygenation products of arachidonic acid. Biochem Biophys Res Commun (1986) 1.37
The strategic approach to contraceptive introduction. Stud Fam Plann (1997) 1.37
Estimation of indole-3-acetic acid in gametophytes of the moss, Physcomitrella patens. Planta (1985) 1.36
In vitro kinetics of two human CYP1A1 variant enzymes suggested to be associated with interindividual differences in cancer susceptibility. Biochem Biophys Res Commun (1997) 1.34
Enhanced drug metabolism in cigarette smokers. Br Med J (1976) 1.31
Role of macrophage migration inhibitory factor (MIF) in murine antigen-induced arthritis: interaction with glucocorticoids. Clin Exp Immunol (2001) 1.29
Characterization of a human glutathione S-transferase mu cluster containing a duplicated GSTM1 gene that causes ultrarapid enzyme activity. Mol Pharmacol (1997) 1.26
A novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in a black African population: association with diminished debrisoquine hydroxylase activity. Br J Clin Pharmacol (1996) 1.26
Role of CYP2C9 polymorphism in losartan oxidation. Drug Metab Dispos (2001) 1.23
Characterisation and PCR-based detection of a CYP2A6 gene deletion found at a high frequency in a Chinese population. FEBS Lett (1999) 1.23
Inhibition of ethanol-induced liver disease in the intragastric feeding rat model by chlormethiazole. Proc Soc Exp Biol Med (2000) 1.21
Mechanisms of hydroxyl radical formation and ethanol oxidation by ethanol-inducible and other forms of rabbit liver microsomal cytochromes P-450. J Biol Chem (1984) 1.21
Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. J Pharmacol Exp Ther (1995) 1.21
Do medical courses adequately prepare interns for safe and effective prescribing in New South Wales public hospitals? Intern Med J (2009) 1.20
Herbal hepatotoxicity: an expanding but poorly defined problem. J Gastroenterol Hepatol (2000) 1.19
Lung cancer risks in women with previous breast cancer. Eur J Cancer (2002) 1.19
Differential alterations of cytochrome P450 proteins in livers from patients with severe chronic liver disease. Hepatology (1995) 1.18
PCR-based genotyping for duplicated and deleted CYP2D6 genes. Pharmacogenetics (1996) 1.17
Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population. Br J Clin Pharmacol (2001) 1.17
Ethanol-, fasting-, and acetone-inducible cytochromes P-450 in rat liver: regulation and characteristics of enzymes belonging to the IIB and IIE gene subfamilies. Biochemistry (1988) 1.16
The Salmonella typhimurium locus mviA regulates virulence in Itys but not Ityr mice: functional mviA results in avirulence; mutant (nonfunctional) mviA results in virulence. J Exp Med (1991) 1.16
Sodium periodate, sodium chlorite, and organic hydroperoxides as hydroxylating agents in hepatic microsomal steroid hydroxylation reactions catalyzed by cytochrome P-450. FEBS Lett (1975) 1.16
The importance of nurse-led home visits in the assessment of children with problematic asthma. Arch Dis Child (2009) 1.15
Institutional rearing, parenting difficulties and marital support. Psychol Med (1984) 1.15
Medical chemistry: evaluation of active and problem-oriented teaching methods. Med Educ (1985) 1.15
Prospective evaluation of serum CA 125 levels in a normal population, phase I: the specificities of single and serial determinations in testing for ovarian cancer. Gynecol Oncol (1990) 1.14
Drug metabolism in liver disease: activity of hepatic microsomal metabolizing enzymes. Clin Pharmacol Ther (1979) 1.13
Drug-induced cholestasis. Semin Gastrointest Dis (2001) 1.13
The effect of ethanol-induced cytochrome p4502E1 on the inhibition of proteasome activity by alcohol. Biochem Biophys Res Commun (2000) 1.13
Microcirculatory and mast cell changes in restraint-induced gastric ulcer. Gastroenterology (1966) 1.13
Zonation of cytochrome P450 isozyme expression and induction in rat liver. Eur J Biochem (1992) 1.12
Genetic mechanisms for duplication and multiduplication of the human CYP2D6 gene and methods for detection of duplicated CYP2D6 genes. Gene (1999) 1.11
Pharmacogenomics of drug-metabolizing enzymes: a recent update on clinical implications and endogenous effects. Pharmacogenomics J (2012) 1.11
Detection of intratumoral aromatase in breast carcinomas. An immunohistochemical study with clinicopathologic correlation. Am J Pathol (1992) 1.11
Effects of chronic ethanol on growth hormone secretion and hepatic cytochrome P450 isozymes of the rat. J Pharmacol Exp Ther (1993) 1.10
PPARgamma inhibits hepatocellular carcinoma metastases in vitro and in mice. Br J Cancer (2012) 1.10
Interindividual differences in hepatic expression of CYP3A4: relationship to genetic polymorphism in the 5'-upstream regulatory region. Biochem Biophys Res Commun (1999) 1.10
A trial of lipotropic enzymes in atheromatous ("arteriosclerotic") dementia. Angiology (1969) 1.10